Table 3.
sUCTD clinical data
| UCTD | N=141 |
| Presenting symptoms, no (%) | |
| Arthralgias/arthritis | 73 (51.7) |
| Raynaud’s phenomenon | 70 (49.6) |
| Skin rash (any type) | 25 (17.7) |
| Constitutional | 22 (15.6) |
| Haematologic | 16 (11.35) |
| Sicca syndrome | 15 (10.6) |
| Serositis | 3 (2.1) |
| Cumulative disease manifestations, no (%) | |
| Articular | 98 (69.5) |
| Raynaud’s phenomenon | 94 (66.6) |
| Sicca syndrome | 65 (46) |
| Constitutional | 65 (46) |
| Skin rash (any type) | 34 (24.1) |
| Haematologic | 23 (16.3) |
| Serositis | 5 (3.5) |
| Immunological characteristics, no/total number of test available (%) | |
| ANA+ | 141/141 (100) |
| Anti-Ro | 36/132 (27.3) |
| aPL+, no (%) | 35/141 (24.8) |
| Anti-RNP+, no (%) | 7/127 (5.5) |
| Anti-dsDNA+ | 7/134 (5.22) |
| Anti-La | 6/131 (4.5) |
| Anti-Sm+, no (%) | 2/127 (1.6) |
| Direct Coomb’s test, no (%) | 16/111 (14.4) |
| Hypocomplementaemia, no (%) | 64/141 (45.3) |
| Comorbidities, no (%) | |
| None | 33 (24) |
| Autoimmune thyroiditis | 41 (29) |
| Fibromyalgia | 38 (26) |
| Arterial hypertension | 19 (13.4) |
| Steoporosis | 15 (10.6) |
| Autoimmune gastritis | 4 (2.8) |
| Coeliac disease | 3 (2.1) |
| Psoriasis | 3 (2.1) |
| Primary biliary cirrhosis | 2 (1.4) |
sUCTD, stable UCTD; UCTD, undifferentiated connective tissue disease.